Source: Virtual Congress 2021 – Advances in asthma treatment: monoclonal antibodies



Rating:

Share or cite this content

Citations should be made in the following way:
A. Gomez-Bastero Fernandez (Sevilla, Spain), E. Chiner (Alicante, Spain), C. Cisneros Serrano (Madrid, Spain), J. Igea (Salamanca, Spain), E. Villamañán Bueno (Madrid, Spain), M. Rial (A Coruña, Spain), M. Pla Martí (Valencia, Spain), V. López Carrasco (Madrid, Spain), A. Martínez Meca (Madrid, Spain), L. Fernández Lisón (Cáceres, Spain), M. Sánchez-Herrero (Madrid, Spain), B. Velasco-Laorga (Madrid, Spain). Spanish consensus on the characteristics of severe asthmatic patients under biological treatment suitable for at home administration. 3728

Member's Comments

No comment yet.

Related content which might interest you: Baseline characteristics of severe asthma patients initiating biologic treatment worldwide Source: Virtual Congress 2021 – Severe asthma: evaluation using patient-reported outcome measures (PROMs) and biomarkers, comorbidities and treatments Year: 2021 Identifying patients with severe asthma that will be benefit from biological therapy Source: Virtual Congress 2020 – Rethinking asthma Year: 2020 Spanish study on unmet clinical needs in patients with uncontrolled severe asthma. Source: International Congress 2018 – Asthma management Year: 2018 Physical activity pattern of severe asthmatic patients treated with biological therapy. Source: International Congress 2019 – Clinical aspects of airway diseases Year: 2019 The study of respiratory function in children with asthma receiving basic therapy Source: International Congress 2017 – Diagnostic tools in paediatric asthma Year: 2017 MARTE: an observational study on clinical and sociodemographic characteristics of asthmatic patients receiving maintenance and rescue treatment in Spain Source: International Congress 2018 – Asthma: clinical screening tools Year: 2018 The prevalence of severe asthma in specialist care –identifying eligible candidates for biological therapies Source: International Congress 2017 – Clinical points to ponder in asthma Year: 2017 The peculiarities of medical treatment at home of patients with COPD aggravated by the serious respiratory deficiency Source: Eur Respir J 2001; 18: Suppl. 33, 73s Year: 2001 Comparison of inhaler device preference of the physicians in the treatment of newly diagnosed adult asthma and COPD patients Source: International Congress 2019 – Inhalers: adherence and preference Year: 2019 Audit of patients admitted with asthma for appropriate treatment changes, self management and follow up Source: Annual Congress 2010 - Innovations in the assessment of airway diseases Year: 2010 Comparison of functionality and symptoms in COPD patients with different nutritional status Source: International Congress 2016 – Treatment and assessment of functional outcomes in cardiorespiratory physiotherapy Year: 2016 Assessing the utility of asthma medication monitoring sensors in a group of high risk asthmatic children Source: International Congress 2017 – Paediatric asthma: treatment modalities and behavioural issues Year: 2017 "It‘s like living with a time bomb"– European patients‘ perspective on severe asthma symptoms Source: Annual Congress 2005 - Severe asthma: perception and management Year: 2005 Treatment eligibility of mepolizumab-treated severe asthma patients in clinical practice Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019 The influence of different schemes of basic treatment on functional indices in moderate–severe asthma patients Source: Eur Respir J 2006; 28: Suppl. 50, 54s Year: 2006 Analysis of two-year treatment with omalizumab patients with severe asthma in real clinical practice Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019 The role of the individual rehabilitation programs in the complex treatment of the patients with bronchial asthma Source: Eur Respir J 2004; 24: Suppl. 48, 519s Year: 2004 Physician assessment of asthma control in patients receiving omalizumab in a real-world setting Source: Annual Congress 2012 - Asthma treatment: efficacy and safety Year: 2012 Are current treatment recommendations suited to elderly patients with asthma or COPD? Source: Eur Respir Mon; 2009: 43: 267–285 Year: 2009 Omalizumab decreases medical resource utilisation in patients with severe allergic asthma in an Italian real-life setting Source: International Congress 2017 – Asthma management Year: 2017